Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (BMY)
NYSE:BMY
BMY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$39.35 - $63.33
Previous CloseN/A
Volume3.98M
Average Volume (3M)13.52M
Market Cap
$103.18B
Enterprise Value$155.61B
Total Cash (Recent Filing)$5.13B
Total Debt (Recent Filing)$6.29B
Price to Earnings (P/E)―
Beta0.14
Next Earnings
Apr 24, 2025EPS Estimate
1.52Last Dividend Ex-Date
Apr 04, 2025Dividend Yield4.77%
Share Statistics
EPS (TTM)-4.43
Shares Outstanding2,034,763,200
10 Day Avg. Volume15,231,899
30 Day Avg. Volume13,522,541
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.57
Price to Cash Flow (P/CF)7.00
P/FCF Ratio7.60
Enterprise Value/Market Cap1.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.28
Enterprise Value/Ebitda49.31
Forecast
1Y Price Target
$58.86Price Target Upside16.07% Upside
Rating ConsensusHold
Number of Analyst Covering17
---
Bulls Say, Bears Say
Bulls Say
EarningsIncreased Eliquis global revenues to $3.35B, indicating a mid-single-digit global growth rate for the brand.
Revenue GrowthCobenfy scripts are tracking ahead of what is needed to beat consensus estimates for 1Q25 revenue, with expectations increased to $28.5M, which is 42% above consensus.
Strategic ManagementManagement has made pragmatic strategic decisions to steer the company through patent cliffs, focusing on driving efficiencies with cost-cutting initiatives and investing in a new growth portfolio.
Bears Say
Market UncertaintyUncertainty remains about when earnings will trough later in the decade, even as approvals ramp across multiple new product cycles.
Product RevenueReduced Opdivo global revenues to $2.20B from $2.26B due to slowing dynamics and the brand's maturity.
Revenue DeclineThere remains a significant gap to bridge the expected declines in revenues in the coming years.
---
Ownership Overview
0.05% Insiders
21.63% Mutual Funds
16.24% Other Institutional Investors
37.81% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BMY FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest stock price was $39.35 and its highest was $63.33 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Bristol-Myers Squibb’s market cap is $103.18B.
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s upcoming earnings report date is Apr 24, 2025 which is in 9 days.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Feb 06, 2025. The company reported $1.67 earnings per share for the quarter, beating the consensus estimate of $1.463 by $0.207.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Undervalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb pays a Quarterly dividend of $0.62 which represents an annual dividend yield of 4.77%. See more information on Bristol-Myers Squibb dividends here
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is 1.52.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,034,763,200 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of $1.67 in its last earnings report, beating expectations of $1.463. Following the earnings report the stock price went down -3.843%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Currently, no hedge funds are holding shares in BMY
---
Bristol Myers Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$58.86 (16.07% Upside)
$58.86 (16.07% Upside)
Blogger Sentiment
Bullish
BMY Sentiment 94%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 4.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $210.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.31%
12-Months-Change
Fundamentals
Return on Equity
-39.10%
Trailing 12-Months
Asset Growth
-2.69%
Trailing 12-Months
Company Description
Bristol-Myers Squibb
Bristol-Myers Squibb (BMY) is a global biopharmaceutical company headquartered in New York City, specializing in the discovery, development, and delivery of innovative medicines that help patients prevail over serious diseases. The company's core therapeutic areas include oncology, immunology, cardiovascular, and fibrosis. Bristol-Myers Squibb is known for its strong portfolio of pharmaceuticals that address critical needs in the treatment of cancer, autoimmune diseases, and heart conditions.
---
BMY Company Deck
---
BMY Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive sentiment with strong growth in the company's key growth portfolio and significant achievements in commercial and R&D milestones. However, challenges remain in the legacy portfolio and impacts from Medicare Part D redesign. The company's strategic focus on operational excellence and financial discipline, along with accelerated R&D productivity, supports a positive outlook.Read More>---
BMY Revenue Breakdown
70.61% U.S.
27.33% International
2.06% Other
---
BMY Stock 12 Month Forecast
Average Price Target
$58.86
▲(16.07% Upside)
Technical Analysis
Best Analysts Covering BMY
1 Year
1 Year Success Rate
18/23 ratings generated profit
1 Year Average Return
+7.16%
reiterated a sell rating 6 days ago
Copying Terence Flynn's trades and holding each position for 1 Year would result in 78.26% of your transactions generating a profit, with an average return of +7.16% per trade.
---